NCT07320326Not yet recruiting
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
A Multi-center, Ambispective, Non-interventional, Observational, Registry Study of the Effectiveness of Elranatamab in Patients With Triple-class Exposed Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice in China(ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab)
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 159 (estimated)
- First submitted
- 9 Dec 2025
- Start date
- 30 Dec 2025
- Primary completion date
- 18 Jul 2028
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT07320326
What you commit to
- Study type: Observational
- Planned participants: 159
- From 30 Dec 2025 to the primary completion date, 18 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with documented diagnosis of other cancers prior to the diagnosis of MM
- Patients enrolled in interventional clinical trials of any drug for MM treatment
- Patients with documented diagnosis of other cancers prior to the diagnosis of MM
- Patients enrolled in interventional clinical trials of Elranatamab or any other drug for MM treatment
Lab values
- Patients with incomplete medical records or missing clinical laboratory data that preclude effectiveness evaluation.
Other
- Patients meeting the following criteria will not be included in the study:
- In the retrospective part:
- Patients who, in the opinion of the investigator, have other factors that make them unsuitable for study participation.
- In the prospective part:
- Patients with contraindication listed in the package insert of elranatamab
Who the study is looking for
- Participants with TCE-RRMM who have received or are planning to start Elranatamab treatment according to the local Health Authority approved product label (routine-care).
- Patients must meet the following criteria to be eligible for inclusion in the study:
- In the retrospective part:
- Male or female patients above 18 years old
- Patients diagnosed with RRMM(IMWG)
- Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment
- Patients received at least 1 treatment dose of Elranatamab treatment after commercial launch in China and according to the approved product label (routine-care) in China (consistent with the approved label in China)\*
- Patients understand and voluntarily sign an ICF .
- In the prospective part:
- Male or female patients above 18 years old
- Patients diagnosed with RRMM (IMWG)
- Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment
- Patients treated with elranatamab as monotherapy or a part of combination therapy and according to the approved product label (routine-care) in China (consistent with the approved label in China)\*
- Patient understand and voluntarily sign an ICF. \*Note: If patients received Elranatamab treatment at a Hong Kong site,the treatment must consist the indications approved in Hong Kong.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.